GLP-1 weight-loss drugs linked to reduced psychiatric care in new study

A registry study of nearly 100,000 people in Sweden found periods of GLP-1 use were associated with a 42% lower need for psychiatric hospital care or extended sick leave; rates of depression and anxiety were also lower. Researchers say the study shows a strong association but does not prove causation.

Researchers report that medications known as GLP-1 agonists were associated with lower rates of psychiatric hospital care and extended sick leave in a large registry study. The analysis used health data from nearly 100,000 people in Sweden between 2009 and 2022, including more than 20,000 periods of GLP-1 use. GLP-1 drugs are commonly prescribed to manage type 2 diabetes and, more recently, for weight loss. The study was led by the University of Eastern Finland with collaborators at the Karolinska Institutet and Griffith University and was published in The Lancet. Key findings: - The study followed nearly 100,000 people in Sweden from 2009–2022, with over 20,000 people using GLP-1 medications. - During periods of GLP-1 use, the need for psychiatric hospital care or extended sick leave was 42% lower compared with periods of nonuse. - Researchers report rates of depression were 44% lower and anxiety disorders 38% lower during semaglutide use. - Incidents related to substance use and self-harm were also reported as lower during periods of GLP-1 use. - Authors and outside experts note this is a registry-based study and does not prove that GLP-1 drugs directly improve mental health. Summary: The study identifies a strong association between GLP-1 medication use and lower measures of psychiatric care and work absence, but it does not establish causation. Researchers have proposed possible explanations such as lifestyle changes tied to weight loss, improved blood sugar control, or effects on how the brain processes reward. Further research to determine mechanisms and causality is undetermined at this time.